|
The coronavirus recession is no excuse for Medicaid expansion
The Washington Examiner | Sally C. Pipes
June 1, 2020
States receive at least one federal dollar for every dollar they spend on Medicaid. On average, the federal government sends states $1.50 for every dollar they spend on the program. That federal match gives states a strong incentive to expand their Medicaid programs.
|
|
Metadata Meets COVID-19
Issues and Insights | Henry I. Miller, M.S., M.D. and Andrew I. Fillat
May 28, 2020
We believe it is critical now to establish a set of “metapolicies” – overarching governing actions to deal with the scourge of the COVID-19 pandemic. These metapolicies consist of sets of minimally prescriptive guiding principles, within which specific policies can be crafted. Most people understand that one size does not fit all. . .
Read more. . . |
|
Sally Pipes Discusses Single-Payer Push with Oklahoma Council of Public Affairs
Oklahoma Council of Public Affairs | Sally C. Pipes
May 28, 2020
Watch PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy discuss the push for single-payer during the COVID-19 crisis and her new book (False Premise, False Promise: The Disastrous Reality of Medicare for All) on a virtual webinar with the Oklahoma Council of Public Affairs. |
|
Believing that we’ll have a COVID-19 vaccine anytime soon is naive
Genetic Literacy Project | Henry I. Miller, M.S., M.D.
June 2, 2020
For one thing, there are potential, unknown safety issues, particularly with the new technologies that are being used to make virtually all of the COVID-19 vaccine candidates. And just organizing clinical trials for the necessary large-scale testing will be a massive logistical effort. Furthermore, the medical, ethical, and regulatory bar is high for a vaccine intended for billions of healthy people.
|
|
|
Prof. Salvare and Pete Paystoomuch join Sage the Detective Dog in searching the Drug Pricing Maze for clues about why drug prices are so different. Along the way, they learn that drug prices vary because there are so many different types of drugs, and how we make orphan drugs that treat patients with rare diseases affordable and accessible.
|
|
|
|
